Marker Therapeutics

Yahoo Finance • 16 days ago

Marker Therapeutics GAAP EPS of -$0.12 beats by $0.33, revenue of $1.23M beats by $0.51M

* Marker Therapeutics press release [https://seekingalpha.com/pr/20307922-marker-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business] (MRKR [https://seekingalpha.com/symbol/MRKR]): Q3 GAAP EPS of -$0.12 beats... Full story

Yahoo Finance • 16 days ago

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601 demonstrated 66% objective response rate with 50% complete response in relapsed Non-Hodgkin lymphoma (NHL) patien... Full story

Yahoo Finance • 25 days ago

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignan... Full story

Yahoo Finance • 27 days ago

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data MT-601 demonstrated robust safety profile with no dose limiting toxicities (DLTs) or immune-effector... Full story

Yahoo Finance • 2 months ago

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment OTS product was well tolerated - safety data consistent with other... Full story

Yahoo Finance • 3 months ago

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignan... Full story

Yahoo Finance • 3 months ago

Tuesday's pre-market session: top gainers and losers

Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics. [premarket] GAINERS TICKER CHANGE COMMENT IVVD [https://www.chartmill.com/stock/quote/IVVD/profile] 132.0% Investors witness... Full story

Yahoo Finance • 3 months ago

Marker's lymphoma therapy shows promising response rates in trial

HOUSTON - Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage biotech company with a market capitalization of $16.3 million, reported Tuesday that its Phase 1 APOLLO study of MT-601 therapy demonstrated a 66% objective response rate... Full story

Yahoo Finance • 3 months ago

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating complete response (CR) Favorable safe... Full story

Yahoo Finance • 4 months ago

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignan... Full story

Yahoo Finance • 5 months ago

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignan... Full story

Yahoo Finance • 6 months ago

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced anti-tumor activity Highest enrollment since study launch underscores momentum and signals a positive trial trajectory Clinical data reado... Full story

Yahoo Finance • 6 months ago

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignanc... Full story

Yahoo Finance • 8 months ago

Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference

HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological maligna... Full story

Yahoo Finance • 8 months ago

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, including durable complete responses Secu... Full story

Yahoo Finance • 9 months ago

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

HOUSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignan... Full story

Yahoo Finance • 2 years ago

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Announced complete response in first patient with lymphoma treated with MT-601 in Phase 1 APOLLO trial following CAR T relapse Received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for multiTAA-specific T cell produc... Full story

Yahoo Finance • 2 years ago

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

HOUSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignan... Full story

Yahoo Finance • 2 years ago

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Executed comprehensive non-dilutive agreement with Cell ReadyTM, resulting in an extended financial runway into the fourth quarter of 2025 Appointed Juan Vera, M.D. as President and Chief Executive Officer and Monic Stuart, M.D., MPH, as... Full story

Yahoo Finance • 2 years ago

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

HOUSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignan... Full story